12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IV rigosertib: Phase III discontinued

Onconova discontinued the open-label, international Phase III ONTRAC trial after a planned interim analysis by a DSMB showed that IV rigosertib plus gemcitabine as first-line treatment of metastatic pancreatic cancer was unlikely to meet the primary endpoint of improving OS vs. gemcitabine alone. No safety concerns were reported. The trial planned to enroll about 650 patients...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >